Level Four Financial’s Aurinia Pharmaceuticals AUPH Stock Holding History

Level Four Financial’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$209K	Buy	+9,450	New	+$150K	0.09%	270

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Level Four Financial's AUPH Position: Q3 2021 in Review

Level Four Financial opened a new position in Aurinia Pharmaceuticals (AUPH) in Q3 2021: 9,450 shares worth $209K. The stake represents 0.09% of the portfolio and ranks #270 among its holdings.

167 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

Level Four Financial held 9,450 shares of Aurinia Pharmaceuticals worth $209K as of Q3 2021.
Aurinia Pharmaceuticals was a new Level Four Financial position in Q3 2021.
Aurinia Pharmaceuticals made up 0.09% of Level Four Financial's portfolio in Q3 2021, its #270 holding.
167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Level Four Financial's 13F filing for Q3 2021, filed 12 Oct 2021.